INDIANAPOLIS (AP) -- Eli Lilly and Co. may soon learn the fate of its cardio drug prasugrel, which is expected to become a key money maker for the company as it nears a wave of patent expirations for other products. The Food and Drug Administration could decide by June 26 whether to approve prasugrel, which would be Lilly’s first new drug launched since 2005.
